Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China

被引：0
|
作者：
Huahua Zhang
Yandong Zhang
Chaonan Huang
Jiangfeng Wang
机构：
[1] Fuyang Hospital of Traditional Chinese Medicine,Department of Pharmacy
[2] Fuyang Hospital of Traditional Chinese Medicine,Department of Gynaecology
[3] Ipharmacare Ltd.,Department of Pharmaceutical Services
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：569 / 577
页数：8
相关论文
共 50 条
  • [31] Cost–utility analysis of trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer in Chinese setting
    Shanshan Hu
    Yilai Wu
    Jiajie Luan
    Shuowen Wang
    Guorong Fan
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 17933 - 17942
  • [32] COST-EFFECTIVENESS OF 1-YEAR ADJUVANT TRASTUZUMAB THERAPY FOR EARLY STAGE OF HER2-POSITIVE BREAST CANCER
    Nguyen, T. T. T.
    Yagudina, R.
    Kulikov, A. U.
    VALUE IN HEALTH, 2011, 14 (03) : A165 - A165
  • [33] KATHERINE: Trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with HER2-positive early breast cancer
    Mamounas, Eleftherios P.
    Geyer, Charles E., Jr.
    Huang, Chiun-Sheng
    Mano, Max S.
    Loibl, Sibylle
    Untch, Michael
    Wolmark, Norman
    Rastogi, Priya
    Schneeweiss, Andreas
    Redondo, Andres
    Fischer, Hans H.
    Jacot, William
    Conlin, Alison K.
    Arce-Salinas, Claudia
    Wapnir, Irene L.
    Jackisch, Christian
    DiGiovanna, Michael P.
    Fasching, Peter A.
    Crown, John P.
    Wuelfing, Pia
    Shao, Zhimin
    Caremoli, Elena Rota
    Wu, Haiyan
    Lam, Lisa H.
    Tesarowski, David
    Smitt, Melanie
    Douthwaite, Hannah
    Singel, Stina M.
    von Minckwitz, Gunter
    SWISS MEDICAL WEEKLY, 2019, 149 : 13S - 13S
  • [34] Irinotecan plus trastuzumab as a second-line treatment for HER2-positive gastric cancer
    Maeda, Osamu
    Ando, Takafumi
    Ishiguro, Kazuhiro
    Watanabe, Osamu
    Miyahara, Ryoji
    Nakamura, Masanao
    Funasaka, Kohei
    Goto, Hidemi
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 224 - 225
  • [35] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Amir Ansaripour
    Carin A. Uyl-de Groot
    W. Ken Redekop
    PharmacoEconomics, 2018, 36 : 91 - 103
  • [36] Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer
    Leung, John Hang
    Tai, Yun-sheng
    Wang, Shyh-Yau
    Fion, Hei-Tung Yip
    Tsung-chin, Ho
    Chan, Agnes Lf
    BREAST, 2022, 65 : 91 - 97
  • [37] Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada
    Attard, C. L.
    Pepper, A. N.
    Brown, S. T.
    Thompson, M. F.
    Thuresson, P. -O.
    Yunger, S.
    Dent, S.
    Paterson, A. H.
    Wells, G. A.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (03) : 173 - 188
  • [38] Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy
    Ansaripour, Amir
    Uyl-de Groot, Carin A.
    Redekop, W. Ken
    PHARMACOECONOMICS, 2018, 36 (01) : 91 - 103
  • [39] Cost-effectiveness analysis (CEA) of adjuvant trastuzumab therapy use in HER2-positive early-stage breast cancer (EBC)
    Quintyne, K. I.
    Woulfe, B.
    Dee, A.
    Gupta, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [40] Development of trastuzumab emtansine (Kadcyla®) for thetreatment of HER2-positive breast cancer
    Phillips, Gail
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2015, 250
12345